Evidence map›Paper›PMID 37704939›Full record

ArticleThe journal of physiological sciences : JPS2023

Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction.

Toru Kawada, Meihua Li, Akitsugu Nishiura, Yuki Yoshida, Shohei Yokota, Hiroki Matsushita, Masafumi Fukumitsu, Kazunori Uemura, Joe Alexander, Keita Saku

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of physiological sciences : JPS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Toru KawadaDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan. torukawa@ncvc.go.jp.ORCID 0000-0002-4429-1802
Meihua LiDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Akitsugu NishiuraDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Yuki YoshidaDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Shohei YokotaDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Hiroki MatsushitaDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Masafumi FukumitsuDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Kazunori UemuraDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
Joe AlexanderMedical and Health Informatics, NTT Research, Inc, Sunnyvale, CA, 94085, USA.
Keita SakuDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan.
National Cerebral and Cardiovascular Center · JPMolecular Medicine Research Institute · US

Funding

Japan Agency for Medical Research and Development 22ama121050j0001Japan Science and Technology Agency JPMJPF2018Japan Society for the Promotion of Science 22K08222Ministry of Internal Affairs and Communications SCOPE: JP225006004National Cerebral and Cardiovascular Center 21-2-7National Cerebral and Cardiovascular Center 21-2-9
6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have exerted cardioprotective effects in clinical trials, but underlying mechanisms are not fully understood. As mitigating sympathetic overactivity is of major clinical concern in the mechanisms of heart failure treatments, we examined the effects of modulation of glucose handling on baroreflex-mediated sympathetic nerve activity and arterial pressure regulations in rats with chronic myocardial infarction (n = 9). Repeated 11-min step input sequences were used for an open-loop analysis of the carotid sinus baroreflex. An SGLT2 inhibitor, empagliflozin, was intravenously administered (10 mg/kg) after the second sequence. Neither the baroreflex neural nor peripheral arc significantly changed during the last observation period (seventh and eighth sequences) compared with the baseline period although urinary glucose excretion increased from near 0 (0.0089 ± 0.0011 mg min

Indexed as

GlucoseMyocardial InfarctionAnimalsBaroreflexBenzhydryl CompoundsGlucosidesRatsBenzhydryl CompoundsempagliflozinGlucoseGlucosidesArterial pressureEquilibrium diagramSodium–glucose cotransporter 2Sympathetic nerve activityUrine flow

Identifiers

PMID37704939
PMCPMC10717373
OpenAlexW4386699159

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.